Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Nearly six months ago, PTC Therapeutics reported positive interim ... PTC decided to see if others might also be interested in the asset. Novartis has won this competitive process.
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...
PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...
PTC Therapeutics signed a $1billion upfront deal with Novartis for its Huntington's program, with potential milestones of $1.9 billion. Interim Phase 2 data shows PTC518 reduces mutant protein ...